Opiniones y recomendaciones de la Sociedad Argentina de Diabetes Hemoglobina A1c

Otros responsables
Fecha
04/2023
Editorial
Sociedad Argentina de Diabetes
Revista
Revista de la Sociedad Argentina de Diabetes
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
0325-5247
eISSN
2346-9420
ISBN
Idioma
Español
Tipo del evento
Clasificación temática
Palabras clave
Resumen
La estandarización de la hemoglobina A1c (HbA1c) permitióen algunos países su uso para el diagnóstico de la diabetesmellitus (DM) y la prediabetes, además de su empleo en elseguimiento del paciente con DM. Es importante recordar quese trata de una medida indirecta del promedio glucémico duranteel tiempo de vida media del eritrocito, pudiendo verseafectada por variables no glucémicas, como también por interferenciasanalíticas según la metodología empleada para sudeterminación.A continuación, se describen las recomendaciones y consideracionesa tener en cuenta para la determinación de la HbA1ccuando se emplea como criterio diagnóstico de la DM, teniendoen cuenta que al utilizarla para tal fin es necesario que lamedida se realice con métodos certificados y estandarizadosal ensayo utilizado en el Diabetes Control and ComplicationsTrial (DCCT).
The standardization of hemoglobin A1c (HbA1c) allowed in some countries its use for the diagnosis of diabetes mellitus (DM) and prediabetes, in addition to its use in the follow-up of patients with DM. It is important to highlight that it is an indirect measurement of the glycemic average during the halflife of the erythrocyte, and may be affected by non-glycemic variables, as well as by analytical interferences depending on the methodology used for its determination. The recommendations and considerations to take into account for the determination of HbA1c when it is used as a diagnostic criterion for diabetes are described below. In addition, it is important to emphasize that it is essential that the HbA1c measurement be performed with certified and standardized methods to the Diabetes Control and Complications Trial (DCCT)results.
The standardization of hemoglobin A1c (HbA1c) allowed in some countries its use for the diagnosis of diabetes mellitus (DM) and prediabetes, in addition to its use in the follow-up of patients with DM. It is important to highlight that it is an indirect measurement of the glycemic average during the halflife of the erythrocyte, and may be affected by non-glycemic variables, as well as by analytical interferences depending on the methodology used for its determination. The recommendations and considerations to take into account for the determination of HbA1c when it is used as a diagnostic criterion for diabetes are described below. In addition, it is important to emphasize that it is essential that the HbA1c measurement be performed with certified and standardized methods to the Diabetes Control and Complications Trial (DCCT)results.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-nd
